Neurophysiological methodologies: Diagnosis of peripheral nerve disease and assessment of pharmacological agents

Current Opinion in Investigational Drugs

Volumn 11, Issue 1, 2010, Pages 72-79

  Cheah, Benjamin C ^a   Kiernan, Matthew C ^a  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Clinical neurophysiology; Diagnostic test; Electrodiagnosis; Electrophysiology

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; MEXILETINE; TETRODOTOXIN; VALPROIC ACID; ZENARESTAT;

AMYOTROPHIC LATERAL SCLEROSIS; DIABETIC NEUROPATHY; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; HUMAN; MOTOR NERVE; MOTOR NERVE CONDUCTION; MOTOR UNIT; NERVE CONDUCTION; NERVE EXCITABILITY; NERVE STIMULATION; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; SENSORY ANALYSIS; SPINAL MUSCULAR ATROPHY; TREATMENT RESPONSE;

ANIMALS; AXONS; DRUG DISCOVERY; ELECTROMYOGRAPHY; HUMANS; MUSCLE, SKELETAL; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; NEURONS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 74549136697     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. McComas AJ, Fawcett PR, Campbell MJ, Sica RE: Electrophysiological estimation of the number of motor units within a human muscle. J Neurol Neurosurg Psychiatry (1971) 34(2):121-131.
2. Bostock H, Cikurel K, Burke D: Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve (1998) 21(2):137-158.
3. Chong PS, Cros DP: Technology literature review: Quantitative sensory testing. Muscle Nerve (2004) 29(5):734-747.
4. Nardin RA, Rutkove SB, Raynor EM: Diagnostic accuracy of electrodiagnostic testing in the evaluation of weakness. Muscle Nerve (2002) 26(2):201-205.
5. Cho SC, Siao-Tick-Chong P, So YT: Clinical utility of electrodiagnostic consultation in suspected polyneuropathy. Muscle Nerve (2004) 30(5):659-662.
6. Mesrati F, Vecchierini MF: F-waves: Neurophysiology and clinical value. Neurophysiol Clin (2004) 34(5):217-243.
7. Knikou M: The H-reflex as a probe: Pathways and pitfalls. J Neurosci Methods (2008) 171(1):1-12.
8. Daube JR: Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve (2000) 23(10):1488-1502.
9. Fuglsang-Frederiksen A: The role of different EMG methods in evaluating myopathy. Clin Neurophysiol (2006) 117(6): 1173-1189.
10. Bromberg MB: Updating motor unit number estimation (MUNE). Clin Neurophysiol (2007) 118(1):1-8.
11. Bromberg MB, Brownell AA: Motor unit number estimation in the assessment of performance and function in motor neuron disease. Phys Med Rehabil Clin N Am (2008) 19(3): 509-532.
12. Wang FC, Bouquiaux O, De Pasqua V, Delwaide PJ: Changes in motor unit numbers in patients with ALS: A longitudinal study using the adapted multiple point stimulation method. Amyotroph Lateral Scler Other Motor Neuron Disord (2002) 3(1): 31-38.
13. Boe SG, Stashuk DW, Doherty TJ: Motor unit number estimation by decomposition-enhanced spike-triggered averaging: Control data, test-retest reliability, and contractile level effects. Muscle Nerve (2004) 29(5):693-699.
14. Lomen-Hoerth C, Slawnych MP: Statistical motor unit number estimation: From theory to practice. Muscle Nerve (2003) 28(3):263-272.
15. Winhammar JM, Rowe DB, Henderson RD, Kiernan MC: Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 4(4):229-238.
16. Aggarwal A, Nicholson G: Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry (2002) 73(2):199-201.
17. de Carvalho M, Swash M: Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve (2000) 23(3):344-352.
18. de Carvalho M, Scotto M, Lopes A, Swash M: Quantitating progression in ALS. Neurology (2005) 64(10):1783-1785.
19. de Carvalho M, Lopes A, Scotto M, Swash M: Reproducibility of neurophysiological and myometric measurement in the ulnar nerve-abductor digiti minimi system. Muscle Nerve (2001) 24(10):1391-1395.
20. Krishnan AV, Lin CS, Park SB, Kiernan MC: Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 13(1):7-26.
21. Krishnan AV, Phoon RKS, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC: Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 128(Pt 9):2164-2174.
22. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC: Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clin Neurophysiol (2006) 117(5):992-999.
23. Krishnan AV, Kiernan MC: Uremic neuropathy: Clinical features and new pathophysiological insights. Muscle Nerve (2007) 35(3):273-290.
24. Krishnan AV, Lin CS, Park SB, Kiernan MC: Axonal ion channels from bench to bedside: A translational neuroscience perspective. Prog Neurobiol (2009) 89(3):288-313.
25. Vucic S, Kiernan MC: Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 117(7):1458-1466.
26. Vucic S, Kiernan MC: Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 78(8):849-852.
27. Vucic S, Krishnan AV, Kiernan MC: Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 78(11):1202-1208.
28. Vucic S, Kiernan MC: Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 129(Pt 9):2436-2446.
29. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC: Oxaliplatininduced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 32(1):51-60.
30. Kiernan MC, Krishnan AV: The pathophysiology of oxaliplatininduced neurotoxicity. Curr Med Chem (2006) 13(24):2901-2907.
31. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC: Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 12(15):4481-4484.
32. Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC: Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 27(8):1243-1249.
33. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC: Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem (2008) 15(29):3081-3094.
34. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC: Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy. Brain (2009) 132(Pt 10):2712-2723.
35. Lin CS-Y, Macefield VG, Elam M, Wallin BG, Engel S, Kiernan MC: Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 130(Pt 4):985-994.
36. Krishnan AV, Kiernan MC: Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 128(Pt 5): 1178-1187.
37. Freeman R, Chase KP, Risk MR: Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy. Neurology (2003) 60(3):465-470.
38. Farrar MA, Johnston HM, Grattan-Smith P, Turner A, Kiernan MC: Spinal muscular atrophy: Molecular mechanisms. Curr Mol Med (2009) 9(7):851-862.
39. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, Wood J, Acsadi G, Crawford TO, Kissel JT, Krosschell KJ et al: Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE (2009) 4(5):e5268.
40. Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, Foyt HL: Natural progression of diabetic peripheral neuropathy in the zenarestat study population. Diabetes Care (2004) 27(5): 1153-1159.
41. Kiernan MC, Isbister GK, Lin CS, Burke D, Bostock H: Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol (2005) 57(3):339-348.
42. Kiernan MC, Baker MD, Bostock H: Characteristics of late Na+ current in adult rat small sensory neurons. Neuroscience (2003) 119(3):653-660.
43. Isbister GK, Son J, Wang F, Maclean CJ, Lin CS, Ujma J, Balit CR, Smith B, Milder DG, Kiernan MC: Puffer fish poisoning: A potentially life-threatening condition. Med J Aust (2002) 177(11-12): 650-653.
44. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB: Systemic administration of local anesthetics to relieve neuropathic pain: A systematic review and meta-analysis. Anesth Analg (2005) 101(6):1738-1749.
45. Kuwabara S, Misawa S, Tamura N, Kanai K, Hiraga A, Ogawara K, Nakata M, Hattori T: The effects of mexiletine on excitability properties of human median motor axons. Clin Neurophysiol (2005) 116(2):284-289.
46. Henderson RD, Daube JR: Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis. Neurology (2004) 63(9):1670-1674.
47. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, Jillapalli D: Revised statistical motor unit number estimation in the celecoxib/ALS trial. Muscle Nerve (2007) 35(2):228-234.
48. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB: Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 60(1):22-31.
49. Henderson RD, McCombe PA, Ridall GR, Pettitt AN: Bayesian statistics for estimating motor unit numbers. Neurology (2004) 62(Suppl 5):455.
50. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC: Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med (2003) 138(1):40-44.
51. Dubinsky RM, Werner RA, Haig AJ, Miller RC: Will EDX physicians be left behind? The need for blinded studies to evaluate electrodiagnostic studies as a diagnostic test. A report of the American Association of Electrodiagnostic Medicine Task Force on Blinding Research. Positive Waves (2003) 11(Suppl):1-4.
52. Turner MR, Kiernan MC, Leigh PN, Talbot K: Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 8(1):94-109.
53. Katz R: Biomarkers and surrogate markers: An FDA perspective. NeuroRx (2004) 1(2):189-195.